

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Paul J. Maddon et al.
U.S. Serial No : Not Yet Known (continuation of U.S. Serial
No.08/328,500, filed October
25, 1994)
Filed : June 25, 2001
For : DERIVATIVES OF SOLUBLE T-4

1185 Avenue of the Americas
New York, New York 10036
June 25, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

BOX: Patent Applications

SIR:

PRELIMINARY AMENDMENT

Please amend the subject application as follows:

In the specification:

On page 1, lines 3-7, please delete the paragraph which begins
"This application is a continuation-in-part of" and insert the
following paragraph:

--This application is a continuation of U.S. Serial No.
08/328,500, filed October 25, 1994, which is a continuation of
U.S. Serial No. 07/830,489, filed February 5, 1992, now U.S.
Patent No. 5,422,274, which is a divisional of U.S. Serial No.
07/160,348, filed February 24, 1988, now U.S. Patent No.
5,110,906, which is a continuation-in-part of U.S. Serial No.
07/114,244, filed October 23, 1987, now U.S. Patent No.

Applicants: Paul J. Maddon et al.
U.S. Serial No : Not Yet Known
Filed: June 25, 2001
Page 2

5,126,433, which is a continuation-in-part of U.S. Serial No. 06/898,587, filed August 21, 1986, now abandoned, the contents of which are hereby incorporated by reference into this application.--

In the claims:

Please cancel claims and 2-3 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a later-filed application. Please amend claims 4, 6, and 14 under the provisions of 37 C.F.R. §1.121 (c) as follows. A marked up version of amended claims 4, 6, and 14 wherein the deleted material is in brackets and the inserted material is underlined is attached hereto as Exhibit A.

--4. (Amended) A pharmaceutical composition which comprises an effective amount of the therapeutic agent of claim 1 and a pharmaceutically acceptable carrier.--

--6. (Amended) An expression vector encoding the polypeptide of claim1.--

--14.(Amended) A method of producing the therapeutic agent of claim 1 which comprises growing the host vector system of claim 6 under suitable conditions permitting production of the therapeutic agent and recovering the therapeutic agent so produced.--

[illegible]


Remarks:

Claims 1-14 are pending in this application. Applicants have herein canceled claims 2 and 3 without prejudice or disclaimer to their right to pursue the subject matter of these claims in a later-filed application. Applicants have also herein amended claims 4, 6 and 14. This amendment does not involve any issue of new matter. Therefore, entry of this amendment is respectfully requested such that claims 1 and 4-14 will be pending.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invites the Examiner to telephone either of them at the number provided below.

No fee, other than the enclosed \$710.00 filing fee, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorneys for Applicant(s)
Spencer H. Schneider
Registration No. 45,923
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400